Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Trending
Oncology
Awards
CRO Awards
Innovation Awards
Pharma Marketing Awards
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Subscribe
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Trending
Oncology
Awards
CRO Awards
Innovation Awards
Pharma Marketing Awards
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Duchenne muscular dystrophy (DMD)
Pharma
2nd patient dies after Sarepta's DMD gene therapy Elevidys
Sarepta has suspended giving Elevidys to non-ambulatory DMD patients in the commercial setting while it seeks FDA approval of a risk mitigation plan.
Angus Liu
Jun 16, 2025 10:58am
Patient dies after receiving Sarepta's DMD gene therapy Elevidys
Mar 18, 2025 10:34am
A heartwarming review of cardiovascular news, most-loved stories
Feb 14, 2025 9:00am
Sarepta's Elevidys blows sales expectations out of the water
Nov 7, 2024 3:43pm
FDA broadens label for Sarepta's Duchenne gene therapy Elevidys
Jun 21, 2024 7:51am
Italfarmaco wins FDA's blessing for nonsteroidal DMD therapy
Mar 22, 2024 11:05am
